Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report.

Thoracic cancer - 1 Jun 2024

Matsuura Hiroaki, Higo Hisao, Kuribayashi Tadahiro, Tamaoki Akihiko, Nakasuka Takamasa, Uno Mari, Makimoto Go, Ninomiya Kiichiro, Fujii Masanori, Rai Kammei, Ichihara Eiki, Hotta Katsuyuki, Miyahara Nobuaki, Tabata Masahiro, Maeda Yoshinobu, Kiura Katsuyuki, Ohashi Kadoaki

Abstract excerpt

The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antitubercular Agents

Share to ErbB Receptors

Share to Indoles

Share to Lung Neoplasms

Share to Pyrimidines

Share to Tuberculosis, Pulmonary

Source

Open in PubMed Open full text

Identifiers

PMID: 38698706
DOI: 10.1111/1759-7714.15324
PMCID: PMC11168902

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report.PMID 38698706Read ↗

Osimertinib-related Pulmonary Fibrosis, A case report and review of literatureSemantic proximity Read ↗

Tuberculosis in epidermal growth factor receptor mutation in lung adenocarcinoma on treatment with gefitinib/erlotinib.Semantic proximity Read ↗

Acute fulminant hepatitis associated with osimertinib administration in a lung cancer patient with chronic hepatitis B: The first mortality case report.Semantic proximity Read ↗

Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review.Semantic proximity Read ↗

Furmonertinib and intrathecal pemetrexed chemotherapy rechallenges osimertinib-refractory leptomeningeal metastasis in a non-small cell lung cancer patient harboring EGFR20 R776S, C797S, and EGFR21 L858R compound EGFR mutations: a case report.Semantic proximity Read ↗

[Osimertinib for an Elderly Patient with Adenocarcinoma of the Lung Harboring EGFR T790M Mutation Diagnosed Using a Pleural Fluid Cell Block].Semantic proximity Read ↗

Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma.Semantic proximity Read ↗

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature.Semantic proximity Read ↗

Osimertinib for the Treatment of EGFR Mutation-Positive Lung Adenocarcinoma Complicated With Dermatomyositis.Semantic proximity Read ↗

Osimertinib-induced severe bilateral pneumothorax: A case report.Semantic proximity Read ↗

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.Semantic proximity Read ↗

Life-threatening pneumonitis after first-line treatment with osimertinib for primary T790M mutated non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.